Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole-brain radiotherapy combined with anlotinib for EGFR wild-type NSCLC brain metastases
ChiCTR1900027769Phase 2Recruiting
- Sponsor
- Shaoxing People's Hospital
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Shaoxing People's Hospital. Primary endpoints: Progression-free survival of intracranial lesions, Overall response rate and 1 more. Started Nov 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR1900027769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027769.